Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03549910
Other study ID # Huaxi ICU-APRV
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 10, 2020
Est. completion date December 30, 2024

Study information

Verified date April 2024
Source West China Hospital
Contact Yongfang Zhou
Phone 86 18140212276
Email zyfmg@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Animal experimentals have shown that the more physiology-driven airway pressure release ventilation (APRV) methodologies in ARDS may significantly improve alveolar recruitment and gas exchange, increased homogeneity, and attenuate lung injury, without circulatory depression, as compared with conventional low tial volume lung protective ventilation. our previous single centre,random control study showed that clinical benefit for early use of APRV in ARDS. Nonetheless, clinical data on ARDS are still limited, most of them derived from small clinical trials in which variable outdated APRV settings were used, consequently, the findings of these studies were controversial. Additionally, the previous single-centre,random control study showed that clinical benefit for APRV.Therefore,the investigators are ready to design a multiple centres,random control study to further verify the effect of APRV plus protocol in ARDS.


Description:

All the patients included will be randomly assigned to receiving APRV plus protocol or low tidal volume ventilation.


Recruitment information / eligibility

Status Recruiting
Enrollment 840
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Moderate and severe acute respiratory distress syndrome,according to the Berlin definition of ARDS - receiving tracheal intubation and mechanical ventilation was no longer than 48 hours Exclusion Criteria: - Pregnancy - The expected duration of mechanical ventilation was less than 48 hours - Intracranial hypertension (suspected or confirmed) - Neuromuscular disorders that are known to prolong the need for mechanical ventilation - Known or suspected chronic obstructive pulmonary disease(COPD) - Terminal stage of disease - Pneumothorax (drained or not)at enrollment - Treatment with extracorporeal support (ECMO) at enrollment - There was a lack of commitment to life support.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
APRVplus protocol
Physiology-driven APRVplus protocol
Low tidal volume ventilation
Low tidal volume lung protective ventilation

Locations

Country Name City State
China West China Hospital,Sichuan University Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other adverse events related to mechanical ventilation including pneumothorax,VAP,and so on during the mechanical ventilation procedure
Primary mortality mortality at Day28 Day 28
Secondary Mechanical ventilation free days Mechanical ventilation free days at Day28 Day 28
Secondary oxygenation oxygenation index:PaO2:fiO2 from enrollment to Day7
Secondary repiratory system compliance static repiratory system compliance (ml/cmH2O) from enrollment to Day7
Secondary MAP mean arterial pressure during the mechanical ventilation procedure
Secondary sedation depth RASS scores during the mechanical ventilation procedure
Secondary Sedative drug the total dose of Sedative drug during the mechanical ventilation procedure
Secondary successful extubation rate the rate of successful extubation during the mechanical ventilation procedure
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A